Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA approves Amgen and Allergan's KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab)

worldpharmanewsJune 20, 2019

Tag: FDA , Amgen , FDA , biosimilar

PharmaSources Customer Service